|
|
Article: Strong patient data for ALK-Abello's Grazax.(Brief Article)
- Article from:
- Pharma Marketletter
- Article date:
- March 13, 2006
CopyrightCOPYRIGHT 2006 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Danish pharmaceutical group ALK-Abello has welcomed strong patient satisfaction data on Grazax, its investigational oral drug for grass pollen allergy. In a global evaluation of patients' perceptions of the agent's efficacy compared with previous untreated seasons, 82% of treated subjects reported symptom improvement, a 49% benefit over the placebo group (p
According to data from the GT-08 trial, patients were also asked to rate their symptoms daily on a Visual Analog Scale; Grazax patients reported a 31% lower mean daily VAS versus placebo (p
Findings from the longitudinal, double-blind, placebo-controlled, parallel-group study, which involved 634 patients from 51 ...